Почетна › Гојазност › Misisipi
Kliničke studije za Гојазност u državi Misisipi
12 studija za Гојазност traži učesnike na lokacijama u državi Misisipi.
Gradovi u državi Misisipi
Zvanični tekst studije (na engleskom)
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- DelRicht Research at Gulfport Memorial, Gulfport
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07351045A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Olive Branch Family Medical Center, Olive Branch
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07351058Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Sky Integrative Medical Center, Ridgeland
Тражи се учесникФаза 3
Узраст од 18 до 99 · Оба пола · Ажурирано 6. 11. 2026. · NCT07575399A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
- SKY Integrative Medical Center/SKYCRNG, Ridgeland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07845500A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Dynamed Clinical Research, LP d/b/a DM Clinical Research, Gulfport
Тражи се учесникФаза 3
Узраст од 6 до 17 · Оба пола · Ажурирано 4. 11. 2026. · NCT06672549A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Fayette
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07784270Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Prime Health and Wellness /ID# 282254, Fayette
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 27. 10. 2026. · NCT07752979A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Gulfport
- ACCOMPLISH-2 Research Site, Ridgeland
Тражи се учесникФаза 3Здраве особе су добродошле
Узраст од 18 до 79 · Оба пола · Ажурирано 20. 10. 2026. · NCT07654374Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Prime Health and Wellness Sky Clinical Research Network Group, Fayette
Тражи се учесникФаза 3
Узраст од 18 до 99 · Оба пола · Ажурирано 5. 10. 2026. · NCT07684235A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Gulfport
- AURORA-2 Clinical Site, Jackson
- AURORA-2 Clinical Site, Olive Branch
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Gulfport
- AURORA-1 Clinical Site, Jackson
- AURORA-1 Clinical Site, Olive Branch
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07743463Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Gulfport
- ACCOMPLISH-1 Research Site, Ridgeland
Тражи се учесникФаза 3
Узраст од 18 до 79 · Оба пола · Ажурирано 10. 8. 2026. · NCT07654361Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.